Authors
Allison S Betof, Ryan D Nipp, Anita Giobbie‐Hurder, Romany AN Johnpulle, Krista Rubin, Samuel M Rubinstein, Keith T Flaherty, Donald P Lawrence, Douglas B Johnson, Ryan J Sullivan
Publication date
2017/8
Journal
The oncologist
Volume
22
Issue
8
Pages
963-971
Publisher
Oxford University Press
Description
Abstract
Background
Monoclonal antibodies (mAb) targeting PD‐1/PD‐L1 have revolutionized melanoma treatment, yet data regarding effectiveness and tolerability across age groups is limited. We sought to determine the impact of age on overall survival (OS), progression‐free survival (PFS), and rates of immune‐mediated toxicities in patients treated with anti–PD‐1/anti‐PD‐L1 mAb at two academic medical centers.
Methods
We retrospectively collected data on all patients with metastatic melanoma treated with anti‐PD‐1/PD‐L1 mAb between May 2009 and April 2015. We used Kaplan‐Meier and Cox regression analyses to assess OS and PFS and identify factors associated with these outcomes. We also compared rates of autoimmune toxicity across age groups.
Results
Of 254 patients, 57 (22.4%) were <50 years old, 85 (33.5%) were age 50–64, 65 …
Scholar articles
AS Betof, RD Nipp, A Giobbie‐Hurder, RAN Johnpulle… - The oncologist, 2017